LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Earnings for LivaNova PLC (LIVN)
Earnings in 2023 (TTM): $-81,226,000
According to LivaNova PLC's latest financial reports the company's current earnings (TTM) are $-81,226,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of LivaNova PLC
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-81,226,000 | $17.55 M |
| 2022 | $-75,100,000 | $-86,200,000 |
| 2021 | $-124,500,000 | $-135,700,000 |
| 2020 | $-344,000,000 | $-343,300,000 |
| 2019 | $-185,700,000 | $-155,500,000 |
| 2018 | $-247,400,000 | $-189,400,000 |
| 2017 | $121.1 M | $-25,100,000 |
| 2016 | $-33,000,000 | $-62,800,000 |
| 2015 | $89.29 M | $57.85 M |
| 2014 | $79.88 M | $54.89 M |
| 2013 | $75.27 M | $46.36 M |
| 2012 | $60.42 M | $36.08 M |
| 2011 | $48.66 M | $46.73 M |
| 2010 | $38.49 M | $78.45 M |
| 2009 | $27.45 M | $26.72 M |
| 2008 | $-10,599,602 | $-10,334,765 |
| 2007 | $-51,101,332 | $-51,180,107 |
| 2006 | $-58,969,926 | $-59,069,192 |
| 2005 | $-12,192,235 | $-12,218,348 |
| 2004 | $6.99 M | $6.76 M |
| 2003 | $5.31 M | $5.18 M |
| 2002 | $-27,119,088 | $-26,119,905 |
| 2000 | $-5,296,030 | $-3,053,244 |
| 1999 | $-14,000,000 | $-12,500,000 |
| 1998 | $-14,200,000 | $-14,200,000 |
| 1997 | $-11,200,000 | $-11,200,000 |
| 1996 | $-10,100,000 | $-10,100,000 |
| 1995 | $-7,200,000 | $-7,200,000 |
| 1994 | $-5,800,000 | $-5,900,000 |
| 1993 | $-5,100,000 | $-5,100,000 |